• Annexin V-PE Apoptosis Kit: Scope and Evidence

  2026-10-16

  The APExBIO Annexin V-PE Apoptosis Kit, SKU K2281, is documented as a PE-fluorescence assay for detecting Annexin V binding to cell-surface phosphatidylserine. Its principal readout is PS exposure, which the product associates with an early apoptosis-related state; the available materials do not establish apoptosis specificity, quantitative performance, comparative validity, or clinical utility.

• Toremifene: What the Product Record Supports

  2026-10-16

  The APExBIO product record identifies Toremifene as a second-generation selective estrogen-receptor modulator and reports an assay-specific IC50 of approximately 1 ± 0.3 μM in Ac-1 cells. These details support a conceptual focus on estrogen receptor modulation and hormone-responsive cancer research, but they do not substitute for a matched primary study or establish general potency, mechanism, or clinical relevance.

• SB202190 and ECM Internalisation in Cancer Cells

  2026-10-15

  Martinez et al. identified an α2β1 integrin–p38β signaling axis that links extracellular-matrix internalisation to invasive carcinoma-cell migration. The study combined high-content imaging, genetic perturbation, trafficking markers, 2D and 3D invasion models, and patient-expression associations. SB202190 is relevant as a named pharmacological perturbation of p38 signaling, but its dual activity toward p38α and p38β limits attribution to MAPK11 alone. The findings are mechanistically informative yet remain bounded by model systems, assay interpretation, and correlative clinical datasets.

• PSI-7977: What the Evidence Supports

  2026-10-15

  The available APExBIO listing identifies PSI-7977 as product A3738, but provides no chemical description, mechanism, assay data, matched research paper, or outcome statistics. Accordingly, the evidence supports only a cautious product-identity and provenance statement, not a mechanistic, performance, or therapeutic conclusion.

• Tetrazolium (Chloride): Mechanism and Evidence

  2026-10-14

  APExBIO identifies Tetrazolium (chloride), or TTC, as a classical tetrazolium redox indicator whose enzymatic reduction produces a red formazan signal. The product description supports a conceptual role in cell-based metabolic readouts and ex vivo ischemic-tissue staining, but no identity-matched research paper, comparative validation, effect size, sample size, or uncertainty estimate is available here. The signal should therefore be interpreted as a downstream dehydrogenase-associated redox measurement rather than a standalone proof of mitochondrial function, viability, or necrosis.

• Toremifene in Prostate Cancer: Evidence Boundaries

  2026-10-14

  Toremifene is a selective estrogen-receptor modulator with a documented research context in hormone-related cancer biology, but the supplied prostate cancer metastasis study does not test Toremifene or establish a connection between estrogen receptor modulation and the TSPAN18–STIM1 calcium-signaling axis.

• Endogenous Melatonin in LPS-Activated Macrophages

  2026-10-13

  A source-grounded overview of a 2024 Experimental Cell Research study examining how LPS-induced macrophage activation affects endogenous melatonin synthesis, and whether that melatonin feeds back on inflammatory polarization, oxidative stress and apoptosis.

• What the ISG20 Atherosclerosis Evidence Shows

  2026-10-12

  A 2025 study links CLEC5A and ISG20 with atherosclerosis using transcriptomic, eQTL and Mendelian-randomization analyses, with additional model-based validation for ISG20. The findings are biologically suggestive but do not establish a clinical treatment target or prove that altered ISG20 activity independently causes human plaque progression.

• Toremifene and the TSPAN18–STIM1 Evidence Gap

  2026-10-12

  The supplied prostate cancer study supports a TSPAN18–STIM1 mechanism in bone-metastasis models, but it does not test Toremifene. Supplier-reported Toremifene activity therefore cannot be used to establish effects on this pathway, therapeutic benefit, or clinical applicability.

• ORAI2 and Early Salivary Gland Fibrosis

  2026-10-11

  The cited study links ORAI2-mediated store-operated calcium entry to early postirradiation salivary-gland fibrosis through a proposed JNK/NFAT1/TGF-β1 pathway. Its multi-model findings are mechanistically coherent but remain preclinical, with important limits concerning pharmacologic specificity, duration, and clinical applicability.

• Boc-D-FMK: Reading Caspase Evidence

  2026-10-10

  Boc-D-FMK is a cell-permeable pan-caspase inhibitor used to test whether caspase activity contributes to apoptosis and inflammation. This article develops an evidence-centered framework linking its interpretation to the 2025 ATF5–CYP2B6 glioblastoma study without overstating mechanistic or translational conclusions.

• Antimycin A4: Evidence, Uses, and Limitations

  2026-10-09

  Antimycin A4 is presented by APExBIO as a mitochondrial respiratory-chain inhibitor and ATP-citrate lyase inhibitor, but the supplied evidence does not independently validate both mechanisms or establish translational applications. This overview separates catalog claims from the supplied peer-reviewed synthesis paper, evaluates conceptual research uses, and defines the main evidence and applicability limits.

• Candida krusei Apoptosis in Bovine Mammary Cells

  2026-10-09

  A 2023 study found that the yeast and hypha phases of Candida krusei induce apoptosis in bovine mammary epithelial cells through different dominant pathways. Its phase-resolved design links yeast-associated injury mainly to mitochondrial signaling, whereas hypha-associated apoptosis is more closely associated with death ligand/receptor signaling and shared TLR–MAPK responses.

• Luminescent ATP Cell Viability Assay Kit I for Ferroptosis

  2026-10-08

  The Luminescent ATP Cell Viability Assay Kit I provides a rapid, sensitive ATP-based endpoint for studying ferroptosis and cytotoxic responses. This article explains how luciferase luminescence detection can strengthen mechanistic interpretation without treating viability loss as proof of a specific death pathway.

• How Dual-Action Inhibitors Tune p38α Dephosphorylation

  2026-10-08

  A 2024 bioRxiv preprint reports that selected kinase inhibitors can do more than block p38α catalytic activity: they can also favor an activation-loop conformation that makes the regulatory phosphothreonine more accessible to WIP1 phosphatase. The structural and biochemical findings introduce a mechanism for coupling kinase inhibition with accelerated dephosphorylation, while remaining an early, primarily reconstituted-system result rather than a clinical or cellular efficacy demonstration.

8671 records 1/579 page Next 12345 下5页 Last page